ATE273288T1 - 2,3,4,5-tetrahydro-1h-(1,4)benzodiazepin-3- hydroxamsäure als matrix metalloproteinaseinhibitoren - Google Patents

2,3,4,5-tetrahydro-1h-(1,4)benzodiazepin-3- hydroxamsäure als matrix metalloproteinaseinhibitoren

Info

Publication number: ATE273288T1
Authority: AT; Austria
Prior art keywords: benzodiazepine; tetrahydro; hydroxamic acid; matrix metalloproteinase; metalloproteinase inhibitors
Prior art date: 1999-01-27

Application number

AT00909990T

Other languages

English (en)

Inventor

Jay Donald Albright

Santos Efren Guillermo Delos

Jeremy Ian Levin

James Ming Chen

Original Assignee

Wyeth Corp

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1999-01-27

Filing date

2000-01-27

Publication date

2004-08-15

2000-01-27 Application filed by Wyeth Corp filed Critical Wyeth Corp

2004-08-15 Application granted granted Critical

2004-08-15 Publication of ATE273288T1 publication Critical patent/ATE273288T1/de

Links

239000003771 matrix metalloproteinase inhibitor Substances 0.000 title 1
229940121386 matrix metalloproteinase inhibitor Drugs 0.000 title 1
YWCKAVNWINYYFA-UHFFFAOYSA-N n-hydroxy-2,3,4,5-tetrahydro-1h-1,4-benzodiazepine-3-carboxamide Chemical compound C1NC(C(=O)NO)CNC2=CC=CC=C21 YWCKAVNWINYYFA-UHFFFAOYSA-N 0.000 title 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D243/00—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms
- C07D243/06—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4
- C07D243/10—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems
- C07D243/14—1,4-Benzodiazepines; Hydrogenated 1,4-benzodiazepines
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Engineering & Computer Science (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Health & Medical Sciences (AREA)
Bioinformatics & Cheminformatics (AREA)
Physical Education & Sports Medicine (AREA)
Immunology (AREA)
Rheumatology (AREA)
Biomedical Technology (AREA)
Diabetes (AREA)
Neurology (AREA)
Urology & Nephrology (AREA)
Orthopedic Medicine & Surgery (AREA)
Communicable Diseases (AREA)
Neurosurgery (AREA)
Endocrinology (AREA)
Virology (AREA)
Oncology (AREA)
Obesity (AREA)
Emergency Medicine (AREA)
Cardiology (AREA)
Heart & Thoracic Surgery (AREA)
Pain & Pain Management (AREA)
Hematology (AREA)
Molecular Biology (AREA)
Hospice & Palliative Care (AREA)
Tropical Medicine & Parasitology (AREA)
Vascular Medicine (AREA)
Psychiatry (AREA)
Ophthalmology & Optometry (AREA)

AT00909990T 1999-01-27 2000-01-27 2,3,4,5-tetrahydro-1h-(1,4)benzodiazepin-3- hydroxamsäure als matrix metalloproteinaseinhibitoren ATE273288T1 (de)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US23908099A	1999-01-27	1999-01-27
PCT/US2000/001991 WO2000044730A1 (en)	1999-01-27	2000-01-27	2,3,4,5-tetrahydro-1h-[1,4]benzodiazepine-3-hydroxamic acid as matrix metalloproteinase inhibitors

Publications (1)

Publication Number	Publication Date
ATE273288T1 true ATE273288T1 (de)	2004-08-15

Family

ID=22900512

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AT00909990T ATE273288T1 (de)	1999-01-27	2000-01-27	2,3,4,5-tetrahydro-1h-(1,4)benzodiazepin-3- hydroxamsäure als matrix metalloproteinaseinhibitoren

Country Status (25)

Country	Link
EP (1)	EP1147095B1 (de)
JP (1)	JP2002535392A (de)
KR (1)	KR20010101730A (de)
CN (1)	CN1197849C (de)
AR (1)	AR022423A1 (de)
AT (1)	ATE273288T1 (de)
AU (1)	AU767039B2 (de)
BG (1)	BG105736A (de)
BR (1)	BR0007759A (de)
CA (1)	CA2356267A1 (de)
CZ (1)	CZ20012637A3 (de)
DE (1)	DE60012883T2 (de)
EA (1)	EA200100809A1 (de)
ES (1)	ES2223470T3 (de)
HU (1)	HUP0105302A3 (de)
ID (1)	ID29046A (de)
IL (1)	IL144168A0 (de)
NO (1)	NO20013675L (de)
NZ (1)	NZ511885A (de)
PL (1)	PL349025A1 (de)
PT (1)	PT1147095E (de)
SK (1)	SK10422001A3 (de)
TR (1)	TR200102131T2 (de)
WO (1)	WO2000044730A1 (de)
ZA (1)	ZA200104321B (de)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CA2357110A1 (en) *	2001-04-11	2002-10-11	American Cyanamid Company	Method for the treatment of polycystic kidney disease
US7585493B2 (en)	2001-05-24	2009-09-08	Alexza Pharmaceuticals, Inc.	Thin-film drug delivery article and method of use
US20070122353A1 (en)	2001-05-24	2007-05-31	Hale Ron L	Drug condensation aerosols and kits
US7458374B2 (en)	2002-05-13	2008-12-02	Alexza Pharmaceuticals, Inc.	Method and apparatus for vaporizing a compound
US20030051728A1 (en)	2001-06-05	2003-03-20	Lloyd Peter M.	Method and device for delivering a physiologically active compound
US7090830B2 (en)	2001-05-24	2006-08-15	Alexza Pharmaceuticals, Inc.	Drug condensation aerosols and kits
WO2003016248A2 (en)	2001-08-17	2003-02-27	Bristol-Myers Squibb Company Patent Department	Bicyclic hydroxamates as inhibitors of matrix metalloproteinases and/or tnf-$g(a) converting enzyme (tace)
BR0213736A (pt)	2001-11-01	2004-10-19	Wyeth Corp	ácidos hidroxâmicos de sulfonamida de arila alênica como metaloproteinase matriz e inibidores de tace
PE20030701A1 (es)	2001-12-20	2003-08-21	Schering Corp	Compuestos para el tratamiento de trastornos inflamatorios
US7488754B2 (en)	2002-04-05	2009-02-10	Wyeth	Method for the treatment of polycystic kidney disease
MXPA05001603A (es)	2002-08-13	2005-04-25	Warner Lambert Co	Derivados monociclicos como inhibidores de metaloproteinasa de matriz.
US7199155B2 (en)	2002-12-23	2007-04-03	Wyeth Holdings Corporation	Acetylenic aryl sulfonate hydroxamic acid TACE and matrix metalloproteinase inhibitors
US20040234916A1 (en)	2003-05-21	2004-11-25	Alexza Molecular Delivery Corporation	Optically ignited or electrically ignited self-contained heating unit and drug-supply unit employing same
US7540286B2 (en)	2004-06-03	2009-06-02	Alexza Pharmaceuticals, Inc.	Multiple dose condensation aerosol devices and methods of forming condensation aerosols
CA2572047C (en)	2004-07-21	2014-04-08	Applied Research Systems Ars Holding N.V.	Octahydropyrrolo[2,3,c]pyridine derivatives and pharmaceutical use thereof
EP1781360A1 (de)	2004-08-12	2007-05-09	Alexza Pharmaceuticals, Inc.	Aerosol-arzneiabgabevorrichtung mit perkussiv aktivierten wärmepackungen
EP1865001A1 (de) *	2006-06-08	2007-12-12	Gsf-Forschungszentrum Für Umwelt Und Gesundheit, Gmbh	Spezifische Proteaseinhibitoren und ihre Verwendung in der Krebstherapie
DK2041181T3 (da) *	2006-06-08	2011-08-29	Helmholtz Zentrum Muenchen	Specifikke proteaseinhibitorer og deres anvendelse i cancerterapi
WO2008112661A2 (en)	2007-03-09	2008-09-18	Alexza Pharmaceuticals, Inc.	Heating unit for use in a drug delivery device
FR2950057B1 (fr)	2009-09-17	2011-08-26	Galderma Res & Dev	Nouveaux composes benzene-carboxylamides, leur procede de synthese et leur utilisation en medecine ainsi qu'en cosmetique
FR2950056B1 (fr)	2009-09-17	2011-08-26	Galderma Res & Dev	Nouveaux composes benzene-carboxylamides, leur procede de synthese et leur utilisation en medecine ainsi qu'en cosmetique
WO2012005229A1 (ja)	2010-07-08	2012-01-12	科研製薬株式会社	Ｎ－ヒドロキシホルムアミド誘導体およびそれを含有する医薬
US9034922B2 (en)	2010-09-17	2015-05-19	The University Of Tokyo	Composition for maintaining function of platelets
US12214118B2 (en)	2018-02-02	2025-02-04	Alexza Pharmaceuticals, Inc.	Electrical condensation aerosol device
CN113194954A (zh)	2018-10-04	2021-07-30	国家医疗保健研究所	用于治疗角皮病的egfr抑制剂
CA3151199A1 (en) *	2019-09-19	2021-03-25	New York Society For The Relief Of The Ruptured And Crippled Maintaining The Hospital For Special Surgery	Stabilized c-fms intracellular fragments (ficd) promote osteoclast differentiation and arthritic bone erosion

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5455258A (en) *	1993-01-06	1995-10-03	Ciba-Geigy Corporation	Arylsulfonamido-substituted hydroxamic acids
ES2153031T4 (es) *	1995-04-20	2001-05-16	Pfizer	Derivados del acido arilsulfonil hidroxamico como inhibidores de mmp y tnf.
US6207672B1 (en) *	1995-11-13	2001-03-27	Aventis Pharma Deutschland Gmbh	Cyclic and heterocyclic N-substituted α-iminohydroxamic and carboxyclic acids
US5753653A (en) *	1995-12-08	1998-05-19	Agouron Pharmaceuticals, Inc.	Metalloproteinase inhibitors, pharmaceutical compositions containing them and their pharmaceutical uses
ES2233275T3 (es) *	1995-12-08	2005-06-16	Agouron Pharmaceuticals, Inc.	Intermediarios que sirven para la preparacion de inhibidores de metaloproteinasas.
KR100339296B1 (ko) *	1996-08-28	2002-06-03	데이비드 엠 모이어	헤테로고리성 메탈로프로테아제 억제제
ATE226573T1 (de) *	1996-08-28	2002-11-15	Procter & Gamble	Heterozyklische metalloproteaseinhibitoren
DE69716934T2 (de) *	1996-08-28	2003-07-31	The Procter & Gamble Company, Cincinnati	1,3-diheterozyklische metalloprotease inhibitoren
EP1051407A1 (de) *	1998-01-27	2000-11-15	American Cyanamid Company	2,3,4,5-tetrahydro-1h-[1,4]-benzodiazepin-3-hydroxamsäure als matrix metalloproteinaseinhibitoren

2000
- 2000-01-26 AR ARP000100323A patent/AR022423A1/es not_active Application Discontinuation
- 2000-01-27 PT PT00909990T patent/PT1147095E/pt unknown
- 2000-01-27 ID IDW00200101465A patent/ID29046A/id unknown
- 2000-01-27 AT AT00909990T patent/ATE273288T1/de not_active IP Right Cessation
- 2000-01-27 BR BR0007759-3A patent/BR0007759A/pt not_active IP Right Cessation
- 2000-01-27 CZ CZ20012637A patent/CZ20012637A3/cs unknown
- 2000-01-27 EP EP00909990A patent/EP1147095B1/de not_active Expired - Lifetime
- 2000-01-27 ES ES00909990T patent/ES2223470T3/es not_active Expired - Lifetime
- 2000-01-27 KR KR1020017009430A patent/KR20010101730A/ko not_active Withdrawn
- 2000-01-27 PL PL00349025A patent/PL349025A1/xx not_active Application Discontinuation
- 2000-01-27 TR TR2001/02131T patent/TR200102131T2/xx unknown
- 2000-01-27 JP JP2000595986A patent/JP2002535392A/ja active Pending
- 2000-01-27 CN CNB008031355A patent/CN1197849C/zh not_active Expired - Fee Related
- 2000-01-27 WO PCT/US2000/001991 patent/WO2000044730A1/en not_active Ceased
- 2000-01-27 NZ NZ511885A patent/NZ511885A/xx unknown
- 2000-01-27 SK SK1042-2001A patent/SK10422001A3/sk unknown
- 2000-01-27 IL IL14416800A patent/IL144168A0/xx unknown
- 2000-01-27 AU AU32160/00A patent/AU767039B2/en not_active Ceased
- 2000-01-27 HU HU0105302A patent/HUP0105302A3/hu unknown
- 2000-01-27 CA CA002356267A patent/CA2356267A1/en not_active Abandoned
- 2000-01-27 DE DE60012883T patent/DE60012883T2/de not_active Expired - Fee Related
- 2000-01-27 EA EA200100809A patent/EA200100809A1/ru unknown
2001
- 2001-05-25 ZA ZA200104321A patent/ZA200104321B/en unknown
- 2001-07-26 BG BG105736A patent/BG105736A/xx unknown
- 2001-07-26 NO NO20013675A patent/NO20013675L/no not_active Application Discontinuation

Also Published As

Publication number	Publication date
AR022423A1 (es)	2002-09-04
PL349025A1 (en)	2002-07-01
JP2002535392A (ja)	2002-10-22
PT1147095E (pt)	2004-12-31
EP1147095B1 (de)	2004-08-11
DE60012883T2 (de)	2005-08-25
ID29046A (id)	2001-07-26
WO2000044730A1 (en)	2000-08-03
AU767039B2 (en)	2003-10-30
ZA200104321B (en)	2002-08-26
TR200102131T2 (tr)	2001-12-21
CN1337952A (zh)	2002-02-27
EA200100809A1 (ru)	2002-02-28
SK10422001A3 (sk)	2002-09-10
NO20013675L (no)	2001-09-21
HUP0105302A2 (hu)	2002-07-29
DE60012883D1 (de)	2004-09-16
ES2223470T3 (es)	2005-03-01
CN1197849C (zh)	2005-04-20
BR0007759A (pt)	2001-11-13
NZ511885A (en)	2003-06-30
CA2356267A1 (en)	2000-08-03
IL144168A0 (en)	2002-05-23
KR20010101730A (ko)	2001-11-14
CZ20012637A3 (cs)	2002-04-17
NO20013675D0 (no)	2001-07-26
BG105736A (en)	2002-05-31
EP1147095A1 (de)	2001-10-24
HUP0105302A3 (en)	2002-09-30
AU3216000A (en)	2000-08-18

Legal Events

Date

Code

Title

Description

2005-03-15

UEP

Publication of translation of european patent specification

Ref document number: 1147095

Country of ref document: EP

2006-10-15

REN

Ceased due to non-payment of the annual fee

Publication	Publication Date	Title
ATE273288T1 (de)	2004-08-15	2,3,4,5-tetrahydro-1h-(1,4)benzodiazepin-3- hydroxamsäure als matrix metalloproteinaseinhibitoren
ATE257151T1 (de)	2004-01-15	Hydroxamsäure-derivate als matrix metalloproteinaseinhibitoren
EE200000720A (et)	2002-04-15	Uus 3-arüül-2-hüdroksüpropaanhappe derivaat (I)
EE200200069A (et)	2003-04-15	Metalloproteinaaside inhibiitoriteks olevad pürimidiin-3,4,6-trioonid
EP1361873A4 (de)	2005-10-26	Matrix-metalloproteinase-hemmer
DK1181017T3 (da)	2003-07-14	Metalloproteaseinhibitorer
EE200000717A (et)	2001-08-15	Uus 3-arüül-2-hüdroksüpropaanhappe derivaat III
DE60009675D1 (de)	2004-05-13	Protonenpumpinhibitoren enthaltende zusammensetzung
DE60008548D1 (de)	2004-04-01	Hydroxamsäurederivate als matrix-metalloproteinase-inhibitoren
NO20003828D0 (no)	2000-07-26	2,3,4,5-Tetrahydro-1H-[1,4]-benzodiazepin-3-hydroksamsyrer som matriks-metalloproteinaseinhibitorer
NO20014243D0 (no)	2001-08-31	Dihetero-substituerte metalloprotease inhibitorer
EE9900180A (et)	1999-12-15	Asendatud 4-bifenüül-4-hüdroksübutaanhappe derivaadid metalloproteaasimaatriksi inhibiitoritena
ATE271541T1 (de)	2004-08-15	Alkinylische hydroxamsäureverbindungen als tace inhibitoren
DK1047665T3 (da)	2004-02-02	Matrix metalloprotease inhibitorer
GB9916562D0 (en)	1999-09-15	3-Arylsulfonyl-2-(substituted-methyl) propanoic acid derivatives as matrix metalloproteinase inhibitora
PL357084A1 (en)	2004-07-12	Thiazepinyl hydroxamic acid derivatives as matrix metalloproteinase inhibitors
ATE205822T1 (de)	2001-10-15	Substituierte 4-arylbutyrsäurederivate als matrix metalloprotease inhibitoren
ATE323673T1 (de)	2006-05-15	Pyrrolidin-2-carbonsäure-hydrazid-derivate als metalloprotease-inhibitoren
ATE227288T1 (de)	2002-11-15	Acetylenische ortho-sulfonamido- und phosphinsäure-amido-bicyclische heteroarylhydroxamsäure als tace-inhibitoren
DK1147095T3 (da)	2004-11-15	2,3,4,5-Tetrahydro-1H-[1,4]benzodiazepin-3-hydroxamsyrer som matrixmetalloproteinaseinhibitorer
FI106001B (fi)	2000-11-15	Hydraulinen tukinkäsittelylaite
IT1308231B1 (it)	2001-12-10	Blocco antisismico.
FI19991956A7 (fi)	2001-03-16	Työajanseurantajärjestelmä